Thursday, September 16, 2010


Biosensors: received CE Mark approval for both the 33mm and 36mm lengths of its BioMatrix Flex drug-eluting stent (DES) system, allowing company to further expand its DES product range from the 8-28mm lengths currently available. This should bolster Biosensors market penetration, as an est 15% of all DES usage involves long lengths. Nomura has a Buy rating with $1.20 target…

Technically, stock is in a longer term uptrend. Support at $0.80 (at 200MA), resistance at $0.90, which if broken could see stock moving toward $1.

No comments:

Post a Comment